

# Study of ESBL- producing *E. coli* in hospitalised horses

---

EMMA WINWARD

SUPERVISORS: DR GINA PINCHBECK & PROF NICOLA WILLIAMS  
UNIVERSITY OF LIVERPOOL

# INTRODUCTION: AMR

---

- One of the greatest challenges in both human and veterinary medicine. Multidrug resistance (MDR) is defined as resistance to 3 or more classes of antimicrobial.
- Resistance may evolve via random mutation or horizontal transfer of mobile genetic elements
- Use of antimicrobials creates a selection pressure for promotion and dissemination of various resistance mechanisms
- **Acquired resistance** can act by:
  - Decreasing drug concentration ( $\downarrow$  permeability or upregulating efflux pump)
  - Modification of target site via mutation or protection
  - Inactivation of antimicrobial via **hydrolysis** or **modification**



# INTRODUCTION: *E. COLI*

---

- Gram negative bacteria belonging to family *Enterobacteriaceae* found commonly as a commensal of the gastrointestinal tract in humans and animals
- Some strains are pathogenic, causing either gastrointestinal or extra-intestinal disease, although commensal strains pose a threat to immunocompromised individuals
- As part of normal GI microflora, inevitably exposed to any antimicrobials administered for clinical infections, thus driving selection pressure for resistance
- Recombination and horizontal gene transfer lead to high genetic diversity

# INTRODUCTION: AMR IN *E. COLI*

---

- Wide range of chromosomal and plasmid-mediated resistance to various classes of antimicrobials reported
- $\beta$ -lactams are a widely used class of antimicrobials including **penicillins, cephalosporins, monobactams** and **carbapemems**
- **$\beta$ -lactamase production** is a type of resistance that hydrolyses the beta-lactam ring inactivating the antimicrobial. Resistance to penicillins, oxyimino-cephalosporins and monobactams
- Genes for  $\beta$ -lactamase production are located on plasmids

# INTRODUCTION: AMR IN *E. COLI*

---

- Most commonly, **extended-spectrum  $\beta$ -lactamase** (ESBL) producing *E. coli* contain TEM, SHV and OXA enzymes
- In 1988, ESBL-producing *E. coli* were discovered which contain **CTX-M enzymes**. These are encoded by ***bla*** genes located on plasmids and are intrinsically resistant to **cephalosporins**
- Since then, over **160 CTX-M enzymes** have been identified across multiple bacterial genera (including *Escherichia*, *Klebsiella* and *Enterobacter*)
- **5 clusters:** CTX-M1, CTX-M2, CTX-M8, CTX-M9 and CTX-M25
  - Based on amino acid sequence

# INTRODUCTION: ESBL-PRODUCING *E. COLI*

---

- **CTX-M-15** (belonging to **Group 1**) is the most prevalent ESBL enzyme isolated in human clinical infections, with MDR *E. coli* clone O25:H4-ST131 showing global dissemination
- **CTX-M-1** (Group 1) and **CTX-M-14** (Group 9) predominate in horses and livestock faeces in the UK
- Maddox *et. al* (2009) identified ESBL-producing *E. coli* in **27.3%** of faecal samples from hospitalised horses, 16.8% of which were **Group 1** positive. At the time they were assumed to be CTX-M-1
- More recent work has identified **CTX-M-15** in equine faecal samples after testing positive as Group 1

# PROJECT AIMS


---

- Investigate the prevalence of *bla*<sub>CTX-M-1</sub> and *bla*<sub>CTX-M-15</sub> genes in previously identified Group 1 positive *E. coli* isolates from hospitalised horses during two different time periods.
- Compare collections of Group 1 positive *bla*<sub>CTX-M</sub> *E. coli* isolates from two cohorts of horses at the same hospital and investigate changes in genotype and epidemiology.
- Investigate the mobility of ESBL genes via conjugation experiments and replicon typing to determine any patterns in ESBL and AMR transfer.

# METHODS: ESBL ISOLATION

---


- Faecal samples were collected daily from inpatients a busy equine hospital in between 2007 and 2009, and again between 2016 and 2017.
- Samples inoculated onto Harlequin agar and Harlequin agar + cefotaxime and incubated at 37°C to select for ESBL-producing *E. coli*
- Antibiotic susceptibility tests were performed using seven clinically relevant antibiotics






# METHODS: ESBL ISOLATION & PCR

- ESBL-producers confirmed via double disc diffusion test and then subject to PCR assays for relevant ESBL genes (*bla*<sub>CTX-M</sub> Universal & CTX-M Group assays) and confirmed as *E. coli* (*uidA* PCR)
- *bla*<sub>CTX-M</sub> Group 1 positive isolates underwent real-time PCR to differentiate between *bla*<sub>CTX-M-1</sub> and *bla*<sub>CTX-M-15</sub> via melt curve analysis.




# RESULTS: COMPARING TWO COHORTS

- **Cohort A:** 457 faecal samples from 103 horses staying at a busy referral hospital 2007-2009
  - **MDR *E. coli*** identified in **47.7%** of samples
  - **ESBL-producing *E. coli*** identified from **27.3%** of samples from **53.4% of horses**
  
- **Cohort B:** 314 faecal samples from 74 horses staying at the same hospital 2016/17
  - **MDR *E. coli*** identified in **61.5%** of samples
  - **ESBL-producing *E. coli*** identified from **50.0%** of samples from **63.5% of horses**




# RESULTS: ESBL GENES

- **Cohort A:** 131 non-duplicate ESBL isolates
  - **16.8%**  $bla_{\text{CTX-M}}$  Group 1 positive
  - Of which, **all** identified as  $bla_{\text{CTX-M-1}}$
- **Cohort B:** 189 non-duplicate ESBL isolates
  - **94.2%**  $bla_{\text{CTX-M}}$  Group 1 positive
  - **66 samples**  $bla_{\text{CTX-M-1}}$  (21%)
  - **91 samples**  $bla_{\text{CTX-M-15}}$  (58%)



# DISCUSSION: COMPARING COHORTS

- Similar proportions of **horses** carrying ESBL-producing *E. coli* within the same hospital. However a higher rate of faecal shedding and more non-duplicate ESBL-producing isolates in 2016/17
- Cohort B had a much higher proportion of  $bla_{CTX-M}$  Group 1 positive isolates
  - **14.5% vs 94.2%**
- Cohort B had a higher proportion of  $bla_{CTX-M-15}$  positive isolates than  $bla_{CTX-M-1}$  positive
  - Cohort A had **no**  $bla_{CTX-M-15}$  positive isolates.
- Higher carriage of MDR *E. coli* in Cohort B compared to Cohort A
  - **61.5% vs 47.7%**



# DISCUSSION: COMPARING COHORTS

---

- Over an 8 year period the prevalence of *bla*<sub>CTX-M</sub> Group 1 positive ESBLs has increased significantly. Within this group, *bla*<sub>CTX-M-15</sub> have become more prevalent.
  - Further work should identify if these isolates are related to the human pandemic strain O25b:ST131
- The proportion of horses carrying ESBLs has remained steady, however a higher proportion of horses carry multi-drug resistant *E. coli*
  - Antibiotic use creates the selection pressure for drug resistance to develop
  - Direct and indirect spread is possible within an equine hospital


# INTRODUCTION: CONJUGATION

---

- **Conjugation** is a type of horizontal gene transfer that requires **direct contact** between bacteria, usually via a **pilus**
- **Plasmids** are self-replicating extra-chromosomal elements that encode various traits including antimicrobial and heavy metal resistance, virulence and environmental adaptations
- Plasmids can be classified by their replication into **Incompatibility (Inc) groups**, whereby two plasmids sharing common replication and partitioning elements cannot proliferate in the same cell line.
- There are **26 known** Inc groups in *Enterobacteriaceae* and particular plasmid types have been associated with virulence and/or antimicrobial resistance.

# METHODS: GENE MOBILITY


- *bla*<sub>CTX-M</sub> Group 1 positive isolates from five equine hospitals were tested for susceptibility to nalidixic acid and streptomycin to pair them with suitable recipient strains
- Donor and recipient strains were inoculated in nutrient broth and incubated overnight, mixed together and incubated for an hour, and then plated onto Muller-Hinton agar containing cefotaxime and nalidixic acid/streptomycin



# METHODS: GENE MOBILITY

---

- Antibiotic susceptibility tests were carried out on conjugated isolates to look for phenotypic transfer of resistance and a *bla*<sub>CTX-M</sub> Group 1 PCR assay used to confirm transfer of ESBL genes.
- Isolates were subject to replicon typing to determine the type of plasmid encoding such resistance.





# RESULTS: AMR IN CONJUGANTS

---

- **159** isolates from 5 hospitals were selected for conjugation experiments. All were MDR ESBL-producing *E. coli* that were *bla*<sub>CTX-M</sub> Group 1 positive.
- Of the **130 isolates** successfully paired with a suitable recipient, 129 transferred resistance to the recipient strain, with **125 (96.9%)** transferring *bla*<sub>CTX-M</sub> Group 1 genes
- Complete phenotypic AMR transfer was seen in **89.9%** of isolates (n=116)
  - **13** isolates did not transfer full phenotypic resistance
  - **8** did **not** transfer resistance to **enrofloxacin**
  - **6** did **not** transfer resistance to **doxycycline**, but 3 of these also lost resistance to enrofloxacin
  - **3** did **not** transfer resistance to more than one antimicrobial

# RESULTS: REPLICON TYPING

Premises/year	Total transconjugants	IncH	Incl	IncF	Notes
Hospital 1, 2008	17	17	1	0	
Hospital 1, 2016	47	8	1	33	5 unidentified
Hospital 2, 2016	28	28	0	0	
Hospital 3, 2016	7	7	1	0	Low prevalence of CTX-M-1
Hospital 4, 2016	3	3	0	0	83.3% resistant to Nal & Strep
Hospital 5, 2016	27	27	4	0	

# RESULTS: REPLICON TYPING CLUSTER

---

- **33** isolates contained **IncF** plasmids, and a further **5** isolates could not identify a plasmid
- All of these are ***bla*<sub>CTX-M-15</sub>** **positive** isolates, whereas all the other isolates within that group and in other groups are ***bla*<sub>CTX-M-1</sub>** positive isolates
- This suggests that within hospital 1 in 2016 a particular plasmid containing multiple antimicrobial resistance genes (including ***bla*<sub>CTX-M-15</sub>**) was circulating within the hospital
  - Further work including full sequencing required to confirm whether the same plasmid containing the same genes was being circulated

# DISCUSSION: GENETIC TRANSFERENCE

---

- High rates of AMR transfer support previous findings that *bla*<sub>CTX-M</sub> genes are located on plasmids
  - Slightly lower rate of fluoroquinolone resistance transfer agrees with studies showing this resistance is determined by a mixture of chromosomal and plasmid genes
- These plasmids containing AMR genes are readily able to replicate and disseminate themselves to other *E. coli* via conjugation
- As plasmids carry multiple resistance genes, this can lead to **co-selection** and therefore resistance to one class of antimicrobial can lead to selection for MDR plasmids or strains
- This high level of genetic transfer could explain why ESBL isolates and MDR *E. coli* prevalence have increased in the last 10 years

# CONCLUSIONS

---

- There is a **high prevalence** of **MDR** and **ESBL-producing *E. coli*** in horses staying in hospitals across the UK.
- **MDR** is encoded by a variety of genes located on **plasmids** that are mobile and apparently easily transferable via **conjugation** in *E. coli*
- Prevalence of **CTX-M-1** ESBL-producing *E. coli* appears to be increasing with time suggesting dissemination of this enzyme
- **CTX-M-15** producing *E. coli* have been identified in equine samples and further work is needed to determine whether these are related to the human pandemic strain.

# CONCLUSIONS

---

- Antimicrobial use creates the selection pressure for resistance gene promotion and dissemination – **good antimicrobial stewardship** prevents this selection
- **Infection control** should also take priority to prevent antimicrobial use and reduce dissemination of these plasmids within an equine hospital
- The risk of these MDR and ESBL-producing genes and their role in **clinical infections** needs further investigation
  - Studies are needed to ascertain presence of these genes in **pathogenic bacteria**
  - Currently studies underway looking at surgical site infections and clinical infections
  - Might be useful to look at the presence of these genes in **in-contact humans** to see if there is inter-species transmission and risk to public health

# ACKNOWLEDGEMENTS

---

Many thanks to:

- Beaufort Cottage Educational Trust
- Professor Nicola Williams, University of Liverpool
- Dr Gina Pinchbeck, University of Liverpool
- Cajsa Isgren, University of Liverpool
- Dr Thomas Maddox, University of Liverpool
- The staff and technical support at Leahurst Campus, University of Liverpool
- The equine hospitals and horse owners that participated in these studies

# REFERENCES

---

- Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. 2014. Molecular mechanisms of antibiotic resistance. *Nature Reviews Microbiology*. Dr Gina Pinchbeck, University of Liverpool
- Bush, K. & Palzkill, T. 2015. *β-Lactamase Classification and Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant Enzymes* [Online]. <http://www.lahey.org/studies/>. [Accessed 22nd June 2016 2016].
- Coque, T. M., Novais, Â., Carattoli, A., Poirel, L., Pitout, J., Peixe, L., Baquero, F., Cantón, R. & Nordmann, P. 2008. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. *Emerging Infectious Diseases*, 14, 195-200.
- Damborg, P., Marskar, P., Baptiste, K.E. and Guardabassi, L., 2012. Faecal shedding of CTX-M-producing Escherichia coli in horses receiving broad-spectrum antimicrobial prophylaxis after hospital admission. *Veterinary microbiology*, 154(3-4), pp.298-304.
- Johns, I., Verheyen, K., Good, L. and Rycroft, A., 2012. Antimicrobial resistance in faecal Escherichia coli isolates from horses treated with antimicrobials: A longitudinal study in hospitalised and non-hospitalised horses. *Veterinary microbiology*, 159(3-4), pp.381-389.
- Levy, S. B. & Marshall, B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med*, 10, S122-9.
- Livermore, D. M. 1995. beta-Lactamases in laboratory and clinical resistance. *Clinical Microbiology Reviews*, 8, 557-84. The staff and technical support at Leahurst Campus, University of Liverpool
- Lavigne, J. P., Marchandin, H., Delmas, J., Bouziges, N., Lecaillon, E., Cavalie, L., Jean-Pierre, H., Bonnet, R. & Sotto, A. 2006. qnrA in CTX-M-producing Escherichia coli isolates from France. *Antimicrobial Agents and Chemotherapy*, 50, 4224-4228.
- Livermore, D. M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G. M., Arlet, G., Ayala, J., Coque, T. M., Kern-Zdanowicz, I., Luzzaro, F., Poirel, L. & Woodford, N. 2007. CTX-M: changing the face of ESBLs in Europe. *Journal of Antimicrobial Chemotherapy*, 59, 165-174.
- Livermore, D. M. & Hawkey, P. M. 2005. CTX-M: changing the face of ESBLs in the UK. *Journal of Antimicrobial Chemotherapy*, 56, 451-454.



# REFERENCES

---

- Maddox, T.W., Clegg, P.D., Williams, N.J. and Pinchbeck, G.L., 2015. Antimicrobial resistance in bacteria from horses: epidemiology of antimicrobial resistance. *Equine veterinary journal*, 47(6), pp.756-765.
- Maddox, T.W., Clegg, P.D., Diggle, P.J., Wedley, A.L., Dawson, S., Pinchbeck, G.L. and Williams, N.J., 2012. Cross-sectional study of antimicrobial-resistant bacteria in horses. Part 1: Prevalence of antimicrobial-resistant *Escherichia coli* and methicillin-resistant *Staphylococcus aureus*. *Equine veterinary journal*, 44(3), pp.289-296.
- Maddox, T.W., Williams, N.J., Clegg, P.D., O'Donnell, A.J., Dawson, S. and Pinchbeck, G.L., 2011. Longitudinal study of antimicrobial-resistant commensal *Escherichia coli* in the faeces of horses in an equine hospital. *Preventive veterinary medicine*, 100(2), pp.134-145.
- Paterson, D. L. & Bonomo, R. A. 2005. Extended-spectrum beta-lactamases: a clinical update. *Clinical microbiology reviews*, 18, 657-+.
- Schmiedel, J., Falgenhauer, L., Domann, E., Bauerfeind, R., Prenger-Berninghoff, E., Imirzalioglu, C. and Chakraborty, T., 2014. Multiresistant extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae from humans, companion animals and horses in central Hesse, Germany. *BMC microbiology*, 14(1), p.187.
- Woodford, N., Ward, M. E., Kaufmann, M. E., Turton, J., Fagan, E. J., James, D., Johnson, A. P., Pike, R., Warner, M., Cheasty, T., Pearson, A., Harry, S., Leach, J. B., Loughrey, A., Lowes, J. A., Warren, R. E. & Livermore, D. M. 2004. Community and hospital spread of *Escherichia coli* producing CTX-M extended-spectrum  $\beta$ -lactamases in the UK. *Journal of Antimicrobial Chemotherapy*, 54, 735-743.
- Woodford, N., Turton, J. F. & Livermore, D. M. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol Rev*, 35, 736-55.
- Wright, G. D. 2011. Molecular mechanisms of antibiotic resistance. *Chemical Communications*, 47, 4055-4061.